Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial
Introduction
Pompe disease (Glycogen storage disease II/GSD II) is an autosomal recessive muscle wasting disorder with an incidence of approximately 1:40,000 [1], [2], [3]. It is caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA) leading to lysosomal glycogen accumulation in different tissues, most severely affecting skeletal and mainly in the infantile form also cardiac muscle. Besides mechanical impairment of muscle fibres, lysosomal accumulation of glycogen leads to rupture of the lysosomes causing secondary damage to the cell [4], [5].
Classical infantile Pompe disease is characterised by progressive, hypertrophic cardiomyopathy, muscular weakness, respiratory insufficiency and death normally within the first year of life [3]. Depending on residual GAA activity, an infantile, a juvenile, and an adult form can be distinguished [6].
In the latter forms, cardiac muscle is usually not affected whereas respiratory impairment and limb girdle muscular weakness are the main clinical features. At present there is no causal therapy available for patients with Pompe disease.
In the development of enzyme replacement therapy, recombinant precursor human acid alpha-glucosidase (rhGAA) was produced in CHO cell cultures [7], [8] and from milk of transgenic rabbits [9], [10]. First data on safety and efficacy of enzyme replacement therapy in classical infantile Pompe disease administering CHO cell derived and a transgenically derived enzyme have been published with encouraging results [11], [12], [13]. In this article we report on data from a phase II clinical trial evaluating safety and efficacy of rhGAA. RhGAA was derived from the milk of transgenic rabbits and administered in weekly infusions with a dosage of 40 mg/kg over a period of 48 weeks.
Section snippets
Materials and methods
This study was designed as a phase II, open-label, single-center, single-dose study. RhGAA was infused once weekly inravenously with 40 mg/kg in two patients. The study was approved by the institutional Ethics Committee, and written informed consent was obtained from the parents prior to any study-related procedure.
Safety
In a total of 96 infusions, eight mild infusion-associated reactions were observed. Patient 1 showed infusion-associated reactions in week 6, 9, and 10 with facial erythema and vomiting. Patient 2 showed a rise in temperature in week 1, 5, 7, tachycardia in week 8 and facial erythema in week 9. Vital parameters were within normal limits at all times besides the mentioned tachycardia. Symptoms resolved quickly after interruption of the infusion and the administration of antihistamines and
Discussion
Enzyme replacement therapy with 40 mg/kg rhGAA weekly enabled survival of the two patients with classical infantile Pompe disease.
At time of enrolment, both patients displayed the typical clinical findings of classical infantile Pompe disease with generalized muscular hypotonia, global delay in motor function and severe cardiomyopathy which necessitated anticongestive medication and intermittent application of additional oxygen via nasal canula. During the course of therapy patient 1 achieved
References (20)
- et al.
Recombinant human α-glucosidase from rabbit milk in Pompe patients
Lancet
(2000) - et al.
Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial
Genet Med
(2001) - et al.
Identification of two subtypes of infantile acid maltase deficiency
J Pediatr
(2000) - et al.
Lancet
(2003) - et al.
Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease
Am J Med Genet
(1998) - et al.
Frequency of glycogen storage disease type II in the Netherlands: implication for diagnosis and genetic counseling
Eur J Hum Genet
(1999) - et al.
Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency
- et al.
The pathology of type II skeletal muscle glycogenosis. A light and electron-microscopic study
J Pathol
(1975) Infantile acid maltase deficiency: Muscle fibre hypertrophy and the ultrastructure of end-stage fibres
Virchows Arch (Cell Pathol)
(1984)- et al.
Biochemical, immunological, and cell genetic studies in glycogenosis type II
Am J Hum Genet
(1978)
Cited by (167)
Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes
2023, Molecular Genetics and Metabolism ReportsLentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease
2022, Molecular Therapy Methods and Clinical DevelopmentTreatment and Management of Hereditary Metabolic Myopathies
2021, Neuromuscular Disorders: Treatment and ManagementImmunogenicity of Protein Pharmaceuticals
2019, Journal of Pharmaceutical SciencesCitation Excerpt :In addition, understanding the disease at the molecular level contributed to the growth of protein-based therapies by identifying key proteins that impact the severity or progression of the disease and harnessing their therapeutic potential to provide treatment. These examples include lifesaving replacement therapies to treat Pompe disease and hemophilia A (HA) with recombinant human acid alpha-glucosidase (rhGAA)1,2 and factor VIII (FVIII),3 respectively, and cytokine-based therapies such as interferon beta for multiple sclerosis.4,5 In addition, monoclonal antibody–based drugs such as adalimumab (Humira), Fc-fusion proteins such as etanercept (Enbrel) for rheumatoid arthritis and Eloctate (Fc-FVIII) and immune checkpoint inhibitors such as pembrolizumab (Keytruda) and atezolizumab (Tecentriq), among several other antibody products, have been developed.
Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase
2018, International Journal of Cardiology